Drugs bill confusion resolved says Germany's drug reimbursement body
This article was originally published in Scrip
A potential faux pas in the wording of Germany' Law on the Reorganization of the Pharmaceutical Market (Arzneimittelmarkt-Neuordnungsgesetz: Amnog), which might have led to manufacturers bypassing value assessment for their products, appears to now been resolved.
You may also be interested in...
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.
An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.